Skip to content

CSL BEHRING

Active
Public limited companyfounded 1995active for 31 yearsBedrijvenlaan 11, 2800 Mechelen, BelgiumKBO/BCE: BE 0454.483.701
Summary

CSL BEHRING has been active since 1995 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €48.3m and a net result of €9.0m. Equity is growing by about 21% per year across the filed financial years. Its solvency ranks better than 58% of 6,131 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).

Financials · financial year 2025, full format

Turnover
€184.4m▲ 16.1%
2024 · €158.9m
EBIT margin
6.6%▲ 1.1pp
2024 · 5.5%
Net result
€9.0m▲ 37.7%
2024 · €6.5m
Working capital
€45.9m▲ 24.5%
2024 · €36.9m
Trend over the years

2020 to 2025, 5 financial years 2020 to 2025, 5 financial years

After the dip in 2023 the operating result has climbed two years in a row; 2025 is 40% above 2024 and is the highest result in the available series.

What the company sold each financial year and what was left of it. A loss stands below the zero line.

Turnover€184.4m 2025 Operating result€12.2m 2025 Net result€9.0m 2025

Use the arrow keys on the chart for the figures per year.

Sector: the middle half of NACE 46, Wholesale trade: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA), Staff (FTE).

Every figure with its change against the financial year before
favourable unfavourable
Line20202022202320242025
Turnover€124.6m-€120.6m-€140.9m▲ 16.8%€158.9m▲ 12.8%€184.4m▲ 16.1%
Operating result€6.0m-€6.7m-€6.4m▼ 4.5%€8.7m▲ 36.3%€12.2m▲ 39.7%
Net result€4.1mabove the sector's middle half-€5.0mabove the sector's middle half-€4.5mabove the sector's middle half▼ 10.8%€6.5mabove the sector's middle half▲ 46.2%€9.0mabove the sector's middle half▲ 37.7%
EBIT margin4.8%-5.6%-4.5%▼ 1.0pp5.5%▲ 0.9pp6.6%▲ 1.1pp
Equity€18.5mabove the sector's middle half-€28.3mabove the sector's middle half-€32.7mabove the sector's middle half▲ 15.8%€39.3mabove the sector's middle half▲ 20.0%€48.3mabove the sector's middle half▲ 22.9%
Total assets€48.3mabove the sector's middle half-€46.0mabove the sector's middle half-€64.4mabove the sector's middle half▲ 40.1%€79.4mabove the sector's middle half▲ 23.3%€92.0mabove the sector's middle half▲ 15.9%
Debt€29.8m-€17.7m-€31.7m▲ 78.8%€40.1m▲ 26.7%€43.8m▲ 9.1%
Working capital€15.9mabove the sector's middle half-€25.8mabove the sector's middle half-€30.3mabove the sector's middle half▲ 17.4%€36.9mabove the sector's middle half▲ 21.7%€45.9mabove the sector's middle half▲ 24.5%
Solvency38.2%within the sector's middle half-61.5%within the sector's middle half-50.8%within the sector's middle half▼ 10.7pp49.5%within the sector's middle half▼ 1.4pp52.4%within the sector's middle half▲ 3.0pp
Current ratio1.53within the sector's middle half-2.46within the sector's middle half-1.96within the sector's middle half▼ 0.501.92within the sector's middle half▼ 0.042.05within the sector's middle half▲ 0.13
Return on assets (ROA)8.5%within the sector's middle half-10.9%above the sector's middle half-6.9%within the sector's middle half▼ 4.0pp8.2%within the sector's middle half▲ 1.3pp9.8%above the sector's middle half▲ 1.5pp
Staff (FTE)30.3above the sector's middle half-31.5above the sector's middle half-33above the sector's middle half▲ 4.8%35.9above the sector's middle half▲ 8.8%36.4above the sector's middle half▲ 1.4%
above within below the middle half of NACE 46, Wholesale trade: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €92.0m
Fixed assets €2.4m ▼ 0.7%
Current assets €89.6m ▲ 16.4%
Equity and liabilities €92.0m
Equity €48.3m ▲ 22.9%
Debt €43.8m ▲ 9.1%
Debt's share of the balance-sheet total falls from 50.5% to 47.6%. Equity and debt are higher.
Key figures and ratios
2025 value · change against 2024
EBITDA
€12.2m▲
2024 · €8.7m
Cash flow
€9.0m▲
2024 · €6.6m
Quick ratio
1.22▼
2024 · 1.25
Debt to equity
0.91▼
2024 · 1.02
ROE
18.6%▲
2024 · 16.6%
Interest coverage
over 100
2024 · over 100
Debt ≤ 1 year
€43.8m▲
2024 · €40.1m
Income taxes
€3.2m▲
2024 · €2.3m
Staff costs
€7.8m▲
2024 · €7.0m
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.

Peer companies

Historical observation

Of the 20,139 companies that looked in July 2024 the way this one looks now, 0.2% went bankrupt within 24 months and 95.0% are still going.

  • Small
  • 20 years or older
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
0.2% went bankrupt
4.7% stopped otherwise
95.0% still going

For this company itself Checked computes a bankruptcy probability of 0.1% over twelve months; the group does not contradict it.

How reliable is this rule?

Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,473 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.

The companies in ten equal groups, from lowest to highest expected share.
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 3.0% 3.1%
10 5.6% 6.2%

The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74.5% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.

An observation about 20,139 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.

Annual accounts
Filed annual accounts As filed with the NBB · 2025 against 2024 · 61 lines
Balance sheet Code20242025
Assets
Total assets20/58€79.4m€92.0m▲
Fixed assets21/28€2.4m€2.4m▼
Tangible fixed assets22/27€0.07m€0.06m▼
Furniture and vehicles24€0.03m€0.03m▼
Other tangible fixed assets26€0.04m€0.03m▼
Financial fixed assets28€2.3m€2.3m=
Affiliated companies280/1€2.3m€2.3m=
Participating interests280€2.3m€2.3m=
Current assets29/58€77.0m€89.6m▲
Stocks and contracts in progress3€27.0m€36.4m▲
Stocks30/36€27.0m€36.4m▲
Goods purchased for resale34€27.0m€36.4m▲
Amounts receivable within one year40/41€49.9m€53.1m▲
Trade receivables40€41.8m€45.7m▲
Other amounts receivable41€8.1m€7.4m▼
Deferred charges and accrued income490/1€0.04m€0.06m▲
Equity and liabilities
Total equity and liabilities10/49€79.4m€92.0m▲
Equity10/15€39.3m€48.3m▲
Contributions10/11€1.7m€1.7m=
Capital10€1.7m€1.7m=
Issued capital100€1.7m€1.7m=
Reserves13€0.2m€0.2m=
Non-distributable reserves130/1€0.2m€0.2m=
Legal reserve130€0.2m€0.2m=
Other1319€16€16=
Tax-exempt reserves132€0.04m€0.04m=
Profit (loss) carried forward14€37.4m€46.4m▲
Amounts payable17/49€40.1m€43.8m▲
Amounts payable within one year42/48€40.1m€43.8m▲
Trade debts44€33.7m€40.5m▲
Suppliers440/4€33.7m€40.5m▲
Taxes, remuneration and social security45€6.5m€3.3m▼
Taxes450/3€4.5m€1.0m▼
Remuneration and social security454/9€2.0m€2.3m▲
Income statement Code20242025
Operating income70/76A€162.4m€191.9m▲
Turnover70€158.9m€184.4m▲
Other operating income74€3.5m€7.5m▲
Operating charges60/66A€153.7m€179.8m▲
Goods for resale, raw materials and consumables60€139.7m€166.7m▲
Purchases600/8€138.6m€176.2m▲
Change in stocks: decrease (increase)609€1.1m-€9.4m▼
Services and other goods61€5.3m€5.2m▼
Remuneration, social security and pensions62€7.0m€7.8m▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€0.03m€0.02m▼
Other operating charges640/8€1.8m€160▼
Operating profit (loss)9901€8.7m€12.2m▲
Financial income75/76B€0.2m€0.2m▲
Recurring financial income75€0.2m€0.2m▲
Other financial income752/9€0.2m€0.2m▲
Financial charges65/66B€0.07m€0.2m▲
Recurring financial charges65€0.07m€0.2m▲
Debt charges650€0.05m€0.06m▲
Other financial charges652/9€0.02m€0.2m▲
Profit (loss) for the period before taxes9903€8.9m€12.2m▲
Income taxes67/77€2.3m€3.2m▲
Taxes670/3€2.3m€3.2m▲
Profit (loss) for the period9904€6.5m€9.0m▲
Profit (loss) for the period to be appropriated9905€6.5m€9.0m▲
Appropriation of the result
Profit (loss) to be appropriated9906€37.4m€46.4m▲
Profit (loss) brought forward from the previous period14P€30.9m€37.4m▲
Social balance sheet
Average headcount (FTE)908735.936.4▲

The notes to these accounts (36 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line20202022202320242025Change
Operating income70/76A-€123.0m€144.0m€162.4m€191.9m▲ 18.2%
Turnover70€124.6m€120.6m€140.9m€158.9m€184.4m▲ 16.1%
Other operating income74-€2.3m€3.1m€3.5m€7.5m▲ 111%
Operating charges60/66A-€116.3m€137.6m€153.7m€179.8m▲ 16.9%
Goods for resale, raw materials and consumables60-€106.8m€122.2m€139.7m€166.7m▲ 19.4%
Purchases600/8-€107.4m€128.9m€138.6m€176.2m▲ 27.1%
Change in stocks: decrease (increase)609--€0.6m-€6.7m€1.1m-€9.4m-
Services and other goods61-€4.1m€5.4m€5.3m€5.2m▼ 1.2%
Remuneration, social security and pensions62-€5.2m€6.6m€7.0m€7.8m▲ 11.5%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€0.06m€0.05m€0.04m€0.03m€0.02m▼ 19.9%
Other operating charges640/8-€0.001m€3.3m€1.8m€160▼ 100.0%
Operating profit (loss)9901€6.0m€6.7m€6.4m€8.7m€12.2m▲ 39.7%
Financial income75/76B-€0.05m€0.006m€0.2m€0.2m▲ 11.0%
Recurring financial income75-€0.05m€0.006m€0.2m€0.2m▲ 11.0%
Other financial income752/9-€0.05m€0.006m€0.2m€0.2m▲ 11.0%
Financial charges65/66B-€0.07m€0.1m€0.07m€0.2m▲ 240%
Recurring financial charges65€0.1m€0.07m€0.1m€0.07m€0.2m▲ 240%
Debt charges650€0.05m€0.05m€0.07m€0.05m€0.06m▲ 17.1%
Other financial charges652/9-€0.01m€0.03m€0.02m€0.2m▲ 898%
Profit (loss) for the period before taxes9903€5.9m€6.7m€6.3m€8.9m€12.2m▲ 37.4%
Income taxes67/77€1.8m€1.7m€1.8m€2.3m€3.2m▲ 36.8%
Taxes670/3-€1.7m€1.8m€2.3m€3.2m▲ 36.8%
Tax adjustments and reversals of tax provisions77-€0.08m----
Profit (loss) for the period9904€4.1m€5.0m€4.5m€6.5m€9.0m▲ 37.7%
Profit (loss) for the period to be appropriated9905€4.1m€5.0m€4.5m€6.5m€9.0m▲ 37.7%
Line20202022202320242025Change
Assets
Total assets20/58€48.3m€46.0m€64.4m€79.4m€92.0m▲ 15.9%
Fixed assets21/28€2.5m€2.4m€2.4m€2.4m€2.4m▼ 0.7%
Tangible fixed assets22/27€0.2m€0.1m€0.1m€0.07m€0.06m▼ 21.1%
Furniture and vehicles24-€0.04m€0.04m€0.03m€0.03m▼ 15.2%
Other tangible fixed assets26-€0.07m€0.06m€0.04m€0.03m▼ 25.0%
Financial fixed assets28€2.3m€2.3m€2.3m€2.3m€2.3m=
Affiliated companies280/1-€2.3m€2.3m€2.3m€2.3m=
Participating interests280-€2.3m€2.3m€2.3m€2.3m=
Current assets29/58€45.8m€43.5m€62.0m€77.0m€89.6m▲ 16.4%
Stocks and contracts in progress3€17.6m€21.4m€28.1m€27.0m€36.4m▲ 34.9%
Stocks30/36-€21.4m€28.1m€27.0m€36.4m▲ 34.9%
Goods purchased for resale34-€21.4m€28.1m€27.0m€36.4m▲ 34.9%
Amounts receivable within one year40/41€28.1m€21.9m€33.5m€49.9m€53.1m▲ 6.4%
Trade receivables40-€21.4m€33.0m€41.8m€45.7m▲ 9.2%
Other amounts receivable41-€0.5m€0.5m€8.1m€7.4m▼ 8.0%
Deferred charges and accrued income490/1-€0.2m€0.3m€0.04m€0.06m▲ 76.9%
Equity and liabilities
Total equity and liabilities10/49€48.3m€46.0m€64.4m€79.4m€92.0m▲ 15.9%
Equity10/15€18.5m€28.3m€32.7m€39.3m€48.3m▲ 22.9%
Contributions10/11€1.7m€1.7m€1.7m€1.7m€1.7m=
Capital10-€1.7m€1.7m€1.7m€1.7m=
Issued capital100-€1.7m€1.7m€1.7m€1.7m=
Reserves13€0.2m€0.2m€0.2m€0.2m€0.2m=
Non-distributable reserves130/1-€0.2m€0.2m€0.2m€0.2m=
Legal reserve130-€0.2m€0.2m€0.2m€0.2m=
Other1319-€16€16€16€16=
Tax-exempt reserves132-€0.04m€0.04m€0.04m€0.04m=
Profit (loss) carried forward14€16.6m€26.4m€30.9m€37.4m€46.4m▲ 24.1%
Amounts payable17/49€29.8m€17.7m€31.7m€40.1m€43.8m▲ 9.1%
Amounts payable within one year42/48€29.8m€17.7m€31.7m€40.1m€43.8m▲ 9.1%
Financial debts43-€4.4m€6.5m---
Other loans439-€4.4m€6.5m---
Trade debts44€22.3m€11.7m€20.6m€33.7m€40.5m▲ 20.3%
Suppliers440/4-€11.7m€20.6m€33.7m€40.5m▲ 20.3%
Taxes, remuneration and social security45-€1.6m€4.6m€6.5m€3.3m▼ 49.4%
Taxes450/3-€0.05m€2.7m€4.5m€1.0m▼ 78.2%
Remuneration and social security454/9-€1.6m€1.9m€2.0m€2.3m▲ 16.9%
Line20202022202320242025Change
Profit (loss) for the period9904€4.1m€5.0m€4.5m€6.5m€9.0m▲ 37.7%
+ Depreciation and write-downs630€0.06m€0.05m€0.04m€0.03m€0.02m▼ 19.9%
Operating cash flow (approximation)€4.2m€5.1m€4.5m€6.6m€9.0m▲ 37.4%
Investment in fixed assets (approximation)---€0.02m-€0.005m-€0.006m▼ 37.9%

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Latest 10 of 34 filings with the National Bank
Financial year Type Filed Reference
30-06-2025 full format 19-12-2025 2025-00585921
30-06-2024 full format 18-12-2024 2024-00618674
30-06-2023 full format 20-11-2023 2023-00513284
30-06-2022 full format 15-12-2022 2022-20537723
30-06-2021 full format 20-12-2021 2021-80800234
30-06-2020 full format 18-12-2020 2020-76100601
30-06-2019 full format 27-12-2019 2019-77600195
30-06-2018 full format 14-03-2019 2019-06900515
30-06-2017 full format 30-01-2018 2018-02600588
30-06-2016 full format 09-02-2017 2017-04100240

Show all 34 filings

Similar companies · same sector, comparable size

Of the 1,869 active companies whose main activity is wholesale of pharmaceutical and medical goods (NACE 46460), figures are known for 1,120. 194 are within a factor 10 of this equity. These 5 are the closest to it. See the whole sector

Public contracts

10 awards · 2025 to 2026
Immunoglobuline humaine normale pour administration intraveineuse: PHARM-2026-845 - 1
buyer: Cliniques universitaires Saint LucMedical equipment and pharmaceuticalsawarded 07-10-2026€16.3m2 tendersTED 731370-2026
Raamovereenkomst voor de aankoop van IV Immunoglobulinen en Protrombine complex concentraat: IV Immunoglobulinen (90% deel)
buyer: VZW Maria MiddelaresMedical equipment and pharmaceuticalsawarded 22-09-2026€19.3m3 tendersTED 658439-2026
Raamovereenkomst voor het leveren van immunoglobulines IV 10%
buyer: Universitair Ziekenhuis GentMedical equipment and pharmaceuticalsawarded 21-09-2026€27.3m3 tendersTED 659219-2026
Aankoop en levering van plasmaderivaten: Intraveneuze immunoglobulinen 100mg/ml
buyer: Algemeen Ziekenhuis Sint-Maria vzwMedical equipment and pharmaceuticalsawarded 09-09-2026€10.5m3 tendersTED 634542-2026
Immunoglobulinen voor intraveneuze toediening (IVIG)
buyer: VITAZ vzwMedical equipment and pharmaceuticalsawarded 31-08-2026€6.9m3 tendersTED 608475-2026
Show 5 more contracts
RO voor het leveren van Humane Immunoglobulinen voor Intraveneuze Toediening - 2026: Raamovereenkomst voor het leveren van Humane Immunoglobulinen voor Intraveneuze Toediening - 2026
buyer: AZ Sint-Jan Brugge AVMedical equipment and pharmaceuticalsawarded 13-07-2026€10.1m4 tendersTED 494556-2026
Intraveneuze immunoglobulinen
buyer: AZ Delta vzwMedical equipment and pharmaceuticalsawarded 18-05-2026€9.7m3 tendersTED 350002-2026
Accord-Cadre pour le traitement de plasma fourni par les établissements de transfusion sanguine agrées par le ministre compétent en Belgique et la garantie aux hôpitaux d'une offre suffisante en dérivés plasmatiques stables (solutions d'albumine et immunoglobulines pour administration intravenineuse) fabriqués à partir du plasma fourni: FODVVVL/Plasmaderivaten/2025/001bis - 1
buyer: SPF Santé Publique Sécurité de la Chaîne Alimentaire et EnvironnementMedical equipment and pharmaceuticalsawarded 01-12-2025€434.6m1 tenderTED 858762-2025
Accord-cadre pour le traitement de plasma fourni par les établissements de transfusion sanguine agrées par le ministre compétent en Belgique et la garantie aux hôpitaux d’une offre suffisante en dérivés plasmatiques stables (solutions d’albumine et immunoglobulines pour administration intraveineuse) fabriqués à partir du plasma fourni: PLASMADERIVATEN/2025/001 - 1
buyer: FOD Volksgezondheid Veiligheid van de Voedselketen en LeefmilieuMedical equipment and pharmaceuticalsawarded 21-08-2025€371.1m1 tenderTED 551621-2025
Raamovereenkomst voor het leveren van polyvalente immunoglobulinen voor subcutane toediening
buyer: Universitair Ziekenhuis GentMedical equipment and pharmaceuticalsawarded 16-05-2025€10.7m2 tendersTED 485586-2025

Source: TED (Tenders Electronic Daily), Publications Office of the European Union. Values as the buyer published them; for a framework agreement, a ceiling.